Share this article
Share this article
SEATTLE, Jan. 20, 2021 /PRNewswire/ Dr. Manon Cox will assume the role of CEO and Dr. Gary Grohmann the role of Chief Regulatory Officer, while retaining their positions on the Board of Directors, along with existing member Michael Bernard, JD, Chief Tax Officer for Vertex, Inc.
Dr. Manon Cox, CEO AVM Biotechnology We are thrilled to have these experienced and respected industry leaders joining our leadership team, as 2021 will be ambitious and exciting for AVM Biotechnology, remarked Dr. Theresa Deisher, AVM Founder. Dr. Deisher will continue in her role as Chairman of the Board and serve as President and Chief Scientific Officer, leading clinical development efforts. Janet R. Rea, MSPH, Chief Operating Officer added, We are eager to work with our expanded team to grow AVM Biotechnology, build our infrastructure, execute our Non-Hodgkin s Lymphoma (NHL) clinical trial, and rapidly move our lead drug AVM0703 toward commercialization.